ECP
FOLD

Elk Creek Partners’s Amicus Therapeutics FOLD Stock Holding History

Elk Creek Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$8.64M Buy
935,002
+75,696
+9% +$720K 1.48% 17
2019
Q4 		$8.37M Sell
859,306
-131,499
-13% -$1.2M 0.96% 44
2019
Q3 		$7.95M Buy
990,805
+172,596
+21% +$1.87M 0.68% 67
2019
Q2 		$10.2M Buy
818,209
+282,001
+53% +$3.58M 0.76% 57
2019
Q1 		$7.29M Buy
+536,208
New +$6.55M 0.53% 79

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Elk Creek Partners's FOLD Position: Q1 2020 in Review

Elk Creek Partners increased its Amicus Therapeutics (FOLD) stake by 8.8% in Q1 2020, buying an estimated $720K and bringing the position to 935,002 shares worth $8.64M. The position accounts for 1.48% of the portfolio, ranked #17.

Elk Creek Partners first reported a position in FOLD in Q1 2019 and has held it in 5 quarters since. The position peaked at $10.2M in Q2 2019. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2020.

  • Elk Creek Partners held 935,002 shares of Amicus Therapeutics worth $8.64M as of Q1 2020.
  • Elk Creek Partners bought 75,696 Amicus Therapeutics shares in Q1 2020, an estimated $720K.
  • Amicus Therapeutics made up 1.48% of Elk Creek Partners's portfolio in Q1 2020, its #17 holding.
  • Elk Creek Partners first reported a position in Amicus Therapeutics in Q1 2019 and has held it in 5 quarters since.
  • Elk Creek Partners's Amicus Therapeutics position peaked at $10.2M in Q2 2019.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.